Sporadic late onset nemaline myopathy (SLONM)

Evidence-based neurology checklist on sporadic late onset nemaline myopathy (slonm): Classification SLOAN without monoclonal protein: this accounts for about 40% of cases SLONM with monoclonal protein: this accounts for about 6o% of cases General features Features of SLOAN with monoclonal protein…

Classification

  • SLOAN without monoclonal protein: this accounts for about 40% of cases
  • SLONM with monoclonal protein: this accounts for about 6o% of cases

General features

Features of SLOAN with monoclonal protein

Associations of SLOAN without monoclonal protein

Magnetic resonance imaging (MRI) muscle: affected sites

Treatments of SLONM with monoclonal gammopathy

Acronym

References

  1. Naddaf E, Milone M, Kansagra A, Buadi F, Kourelis T. Sporadic late-onset nemaline myopathy: clinical spectrum, survival, and treatment outcomes. Neurology 2019; e298-e305.
  2. Paramalingam S, Dyke JM, Nossent JC. Sporadic late onset nemaline myopathy (SLONM) in an adult presenting with progressive muscle weakness. Eur J Rheumatol 2018; 6:1-3. 
  3. Uruha A, Benveniste O. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. Curr Opin Neurol 2017; 30:457-463.
  4. Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, et al. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet J Rare Dis 2017; 12:86.
  5. Kanamori T, Kusumoto S, Okita K, et al. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance mimicking POEMS syndrome. Rinsho Ketsueki 2018; 59:161-166.
  6. And 9 more. Subscribe to see the full list

Related checklists

Loading...